Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.
about
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsCircumventing antivector immunity: potential use of nonhuman adenoviral vectorsImproving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cellsAdenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy.New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity.Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopesChimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.Novel vaccine vectors for HIV-1.Epitope specificity delimits the functional capabilities of vaccine-induced CD8 T cell populations.Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizationsConstruction and evaluation of novel rhesus monkey adenovirus vaccine vectors.The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigenControlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming.Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine ImmunityGerminal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1)Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expressionNew developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.Development of replication-deficient adenovirus malaria vaccines.In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity.Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.Profiling the Targets of Protective CD8+ T Cell Responses to Infection.Strain-dependent and distinctive T-cell responses to HIV antigens following immunisation of mice with differing chimpanzee adenovirus vaccine vectors.Novel Concepts for HIV Vaccine Vector Design.Development of novel vaccine vectors: Chimpanzee adenoviral vectors.Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.Simian adenoviruses as vaccine vectors.Rapid Construction of a Replication-Competent Infectious Clone of Human Adenovirus Type 14 by Gibson Assembly
P2860
Q24273364-5E9F5E8F-00EE-4992-8F09-6058B9EDACAFQ26782083-30D0EE47-168A-42B0-8FF5-82243127899CQ26995655-9292A03E-3B16-40B3-88D8-00F4911333F6Q28543248-90F21991-AEA9-4AB0-84D1-418799569235Q33601808-51BCD51C-E288-4236-B200-B04648471E57Q33762986-E6ABBF30-693A-4BE1-A64B-E7A334A13BB0Q33868760-5EB3AEBB-CA25-46AC-B6DD-19CD7328D73DQ33909362-8F8617DF-2589-4022-A0E1-95B1D2F722ABQ33992101-EB962CE6-AB05-4D11-BA95-834E6B46127EQ34165879-3CF92E4C-F1E7-4733-8A1E-E3014C224B32Q34437167-7E6B0CC2-9637-405C-B999-FDE117D24AA9Q34541191-574E71D6-1D22-45FB-AAFD-D612D0F3E9A6Q34548297-76346EED-7AF9-4401-94EC-9A81EBCBBB9EQ34593874-40A88F97-259F-4AD7-9A96-7DC3A98BC735Q34991437-A5324334-BACC-4900-9350-D1A40F63BE25Q35091556-2EA806E6-DC8F-4B82-8882-8439C11B8175Q35183935-E01C4BBA-E238-4955-BCF3-BD3CC7050164Q35344875-7FD0FECC-C35E-4EEA-A342-E15DDEFA7AD4Q35864569-047CB3AA-1B80-4828-920F-F4AD404335DFQ36192765-BACC9ACB-3473-47BA-AB86-622DAB7578A4Q36369321-455575D3-E86D-402D-BF58-16BA9C837E38Q36389006-8C697D92-AE9D-41DF-8930-4DB26667F0FDQ36394177-09113D8D-2645-47FB-BCF9-DE77C46F5489Q36538834-A3A5DE78-76E9-414F-A62D-E19D361CCFCDQ37153663-1A7BA52F-DADB-4039-904B-C0F27CEC8508Q37530471-90B74FC8-E4B0-4796-83DF-4B77854E5BB1Q37624973-0FAC66EA-12FB-415E-A80C-72C99B9DC931Q38748193-C8E29613-F1C9-4223-94A0-9048A24878FAQ38949194-AFDA0248-C34E-4D65-82D6-81FBC25717FBQ40937108-8859DB0A-216C-4705-8615-EDFC0F368DE4Q41335764-D1BC1DB0-E184-4F12-BA56-FFF2612946A6Q41693606-5578B783-F663-450B-A5C0-6E8094A66BDDQ42107571-62CE26F5-C824-49A2-8B8C-5A73C359CD8BQ47112156-70F711FB-8A1E-4140-8982-FB6E5844A51EQ47558190-0D341660-3795-4288-892A-ED396820CD5DQ47607706-518C8996-A709-4ED5-9167-EBE6CF52D707Q54531277-DFD89645-A183-467E-B7A9-A5EC1CC3DE98Q57812957-AF7EE34C-72CF-4D23-AA11-B5DFA2A64F8D
P2860
Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Comparative analysis of the ma ...... denoviral vector immunization.
@ast
Comparative analysis of the ma ...... denoviral vector immunization.
@en
type
label
Comparative analysis of the ma ...... denoviral vector immunization.
@ast
Comparative analysis of the ma ...... denoviral vector immunization.
@en
prefLabel
Comparative analysis of the ma ...... denoviral vector immunization.
@ast
Comparative analysis of the ma ...... denoviral vector immunization.
@en
P2093
P2860
P50
P921
P356
P1476
Comparative analysis of the ma ...... denoviral vector immunization.
@en
P2093
Alfredo Nicosia
Andreia Da Costa
Antonella Folgori
Ayako Yamamoto
Cecilia Morgan
Cheng Cheng
Dana Berry
Emma Gostick
Jason G D Gall
Linda S Wyatt
P2860
P304
P356
10.4049/JIMMUNOL.1202861
P407
P577
2013-02-06T00:00:00Z